BUDGET IMPACT ANALYSIS OF AN ETANERCEPT BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ETANERCEPT INDICATIONS FOR ADULTS IN EUROPE

被引：0
|
作者：
Ruff, L. [1 ]
Rezk, M. F. [2 ]
Uhlig, T. [3 ]
Gommers, J. W. [2 ]
机构：
[1] Covance Inc, London, England
[2] Biogen Int GmbH, Zug, Switzerland
[3] Diakonhjemmet Hosp, Oslo, Norway
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS33
引用
收藏
页码：A639 / A639
页数：1
相关论文
共 50 条
  • [31] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING AN ADALIMUMAB BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN GERMANY
    Roehrer, W.
    Waker, M.
    Levysohn, A.
    Bodin, M.
    Keady, S.
    [J]. VALUE IN HEALTH, 2019, 22 : S47 - S47
  • [32] Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA
    Kearsley-Fleet, Lianne
    Rokad, Aasiyah
    Tsoi, Man-Fung
    Zhao, Sizheng Steven
    Lunt, Mark
    Watson, Kath D.
    Hyrich, Kimme L.
    [J]. RHEUMATOLOGY, 2023, 63 (08): : 2082 - 2092
  • [33] BUDGET IMPACT OF ETANERCEPT VERSUS ADALIMUMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS IN BIOLOGIC -NAIVE PATIENTS IN THE UNITED KINGDOM
    Onishchenko, K.
    Tarallo, M.
    Curiale, C.
    Alexopoulos, S. T.
    [J]. VALUE IN HEALTH, 2018, 21 : S193 - S194
  • [34] The economic impact of etanercept and infliximab treatment in ankylosing spondylitis
    Duff, SB
    Yeh, Y
    Yu, EB
    Woolley, JM
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 400 - 400
  • [35] Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia
    August Cesarec
    Robert Likić
    [J]. Applied Health Economics and Health Policy, 2017, 15 : 277 - 286
  • [36] Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia
    Cesarec, August
    Likic, Robert
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (02) : 277 - 286
  • [37] IMPACT OF BLOCK SWITCH TO BIOSIMILAR ETANERCEPT IN PRACTICE - AN EXPERIENCE FROM ONE TERTIARY RHEUMATOLOGY DEPARTMENT
    Brites, Luisa
    Costa, Flavio
    de Freitas, Joao Dinis
    Luis, Mariana
    Coutinho, Margarida
    Santiago, Mariana
    Salvador, Maria Joao
    Duarte, Catia
    Jose Antonio Da Silva, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1372 - 1372
  • [38] Budget Impact of Etanercept Versus Adalimumab for Treatment of Rheumatoid Arthritis in Biologic-Naive Patients in the United Kingdom
    Onishchenko, Kateryna
    Tarallo, Miriam
    Curiale, Cinzia
    Alexopoulos, Stamatia Theodora
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [39] NO DIFFERENCE IN EFFECTIVENESS WITH EITHER ETANERCEPT ORIGINATOR OR BIOSIMILAR AS FIRST LINE BIOLOGIC TREATMENT FOR RHEUMATOID ARTHRITIS
    De Cock, D.
    Davies, R.
    Kearsley-Fleet, L.
    Watson, K.
    Hyrich, K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1377 - 1378
  • [40] Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis
    Suzuki, Yutaka
    Inoue, Kazuhiko
    Chiba, Junji
    Inoue, Yasuo
    Kanbe, Katsuaki
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2009, 12 (01) : 7 - 13
12345